RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I program in Paroxysmal Nocturnal Hemoglobinuria. According to Globaldata, it is involved in 1 clinical trial, which was completed. GlobalData uses proprietary data and analytics to provide a complete picture of RLYB-116’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for RLYB-116 is expected to reach an annual total of $415 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RLYB-116 Overview
RLYB-116 is under development for the treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis and other dermatological diseases. It is administered through subcutaneous route. RLYB-116 is a fusion protein which acts by targeting C5. The Affibody domain of RLYB-116 binds with high affinity to C5, thereby inhibiting terminal complement activation, while the Albumod technology albumin-binding domain (ABD) binds with high affinity to serum albumin, thereby extending the plasma half-life of the protein.
Rallybio Overview
Rallybio is a clinical-stage biotechnology company committed on discovering and accelerating the development of life-transforming therapies for patients with severe and rare diseases. The company offers pipeline products such as RLYB212, RLYB114, RLYB116 and RLYB331. RLYB211 is a polyclonal anti-HPA-1a intravenous antibody made from the plasma of women who have previously had an HPA-1 incompatible pregnancy and have produced antibodies to HPA-1a. RLYB114 is used for the treatment of complement-mediated ophthalmic diseases. RLYB116 is an inhibitor of complement component C5, which plays a central role in innate immunity. RLYB331 for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio is headquartered in Farmington, Connecticut, the US.
The operating loss of the company was US$69 million in FY2022, compared to an operating loss of US$47.2 million in FY2021. The net loss of the company was US$66.7 million in FY2022, compared to a net loss of US$47 million in FY2021.
For a complete picture of RLYB-116’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
